Last reviewed · How we verify
Bisoprolol 2.5 mg
At a glance
| Generic name | Bisoprolol 2.5 mg |
|---|---|
| Also known as | Concor, Lowering high blood pressure agent |
| Sponsor | Imperial College London |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- MEdical Treatment in Idiopathic Ventricular Fibrillation Patients (PHASE4)
- An Observational Study to Learn More About the Real-world Outcomes in Patients With Heart Failure Who Initiate Treatment With Vericiguat in Japan
- pErsonalised Nocebo Assessment of Beta-blockEr Symptoms in Heart Failure (NA)
- Heart Failure With Reduced Ejection Fraction Polypill Implementation Strategy in Sri Lanka (PHASE1)
- Treatment Effects of Bisoprolol and Verapamil in Symptomatic Patients With Non-obstructive Hypertrophic Cardiomyopathy (PHASE4)
- Once Versus Twice Bisoprolol Dosage Regimen in Prevention of Atrial Fibrillation Post Coronary Artery Bypass Graft Surgery (PHASE4)
- Nasal Desmopressin Versus Oral Bisoprolol for Controlling Bleeding During Endoscopic Sinus Surgery (PHASE2)
- Left Atrium Reservoir Function Modulation in Patients With Atrial Fibrillation: Digoxin Versus Beta Blocker (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bisoprolol 2.5 mg CI brief — competitive landscape report
- Bisoprolol 2.5 mg updates RSS · CI watch RSS
- Imperial College London portfolio CI